Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antiviral drug |
| gptkbp:ATCCode |
none (not assigned)
|
| gptkbp:CASNumber |
1009119-65-6
|
| gptkbp:developedBy |
Ascletis Pharma
hepatitis C virus protease inhibitor |
| gptkbp:hasMolecularFormula |
C40H53N7O7S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sovaprevir
|
| gptkbp:IUPACName |
(1R,5S,6S,7Z,15R,18S,20S,21S)-6-tert-butyl-N-[(1R,2S)-1-cyclopropyl-2-hydroxy-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]ethyl]-18-(2-methylpropyl)-2,8,14,19,22-pentaoxo-3,9,13,20-tetraazatricyclo[20.3.0.05,7]pentacos-7-ene-21-carboxamide
|
| gptkbp:PubChem_CID |
25154816
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
NS3/4A protease
|
| gptkbp:bfsParent |
gptkb:NS3/4A_serine_protease
|
| gptkbp:bfsLayer |
7
|